Arizona Bioscience News, November 2026

November 12, 2026

By Jessica Vaile

November 2026

LEADERSHIP
Panel discussion at the Finn Foundation Bio Capital Conference with four speakers seated before an audience

Ask founders where to find funding, and they’ll list venture capital firms, angel investors, federal grants, pitch competitions, cold emails.

But ask founders who have successfully closed funding rounds, and you’re likely to hear stories about alternative funders. Their experiences offer practical insights that can challenge assumptions, surface opportunities, and sharpen your approach to raising or investing capital in Arizona’s bioscience sector.

Those are the stories we will showcase at the 2027 Flinn Foundation Bio Capital Conference, scheduled for Thursday, March 4, at Creighton University in Phoenix. The conference is the signature event of the Bioscience Roadmap Steering Committee’s Risk Capital Project Team.

We are assembling a lineup of speakers and panels featuring founders and investors who have navigated the fundraising process. Investors will have the opportunity to meet some of Arizona’s most promising biotech companies. Those companies have the chance to build meaningful relationships with investors who understand their industry.

We are also developing sessions on health economics that offer founders and investors fresh perspectives on what it takes to build, fund, and grow a successful bioscience venture.

Companies, act early. Submit your information for the conference directory by Dec. 1 and receive 50% off the conference ticket. Submit your entry and receive your discount.

Get ready to make connections, hear the stories behind successful investments, and discover funding opportunities where you might not have thought to look.

Professional headshot of a smiling woman with wavy dark hair wearing a navy sweater and white collared shirt
Helen Goldstein
Chair, Risk Capital Project Team
Roadmap Steering Committee 


GRANTEE SPOTLIGHT

A 10-minute test for Valley fever 

Doug Lake, Arizona State University professor and co-founder of Scottsdale-based Cactus Bio, is working on a 10-minute rapid test to diagnose coccidioidomycosis, or Valley fever.

Today’s Valley fever test, which takes between three and five days for a result, may never be given at an urgent care or emergency room, and instead patients may receive a prescription for an ineffective antibiotic.  

Lake, in partnership with Mayo Clinic, was the recipient of a $100,000 grant from the Flinn Foundation Translational Seed Grants Program in 2023. The project team received an additional $100,000 in follow-on funding last year. 

Nearly 15,000 Valley fever cases were reported in 2024 and more than 12,000 last year in Arizona alone, the highest of any state including California.F


HAPPENING THIS WEEK

Arizona is a national leader in the global fight against Alzheimer’s disease 

The big picture: More than 151,000 Arizonans and 7.4 million adults over 65 live with Alzheimer’s disease in the United States. November is National Alzheimer’s Disease Awareness Month.

Arizona, through its support for translational research and guided by Arizona’s Bioscience Roadmap, is making major contributions in identifying new diagnostic tests to help in the prevention and treatment of Alzheimer’s.

The background: This fall, the Flinn Foundation awarded a $1.8 million grant to Nicholas Ashton, Ph.D., and his team at Banner Sun Health Research Institute’s Fluid Biomarker Program to support the investigation of blood-based biomarkers. Ashton, among the most highly cited researchers in his field, helped pioneer Alzheimer’s blood tests in Sweden before joining Banner Health two years ago. 

The program’s two Sun City labs opened in early 2026:

  • The Michael T. Zuendel Family Biofluid Lab runs rapid, rigorous blood and spinal fluid tests for national and international studies and clinical trials. 
  • The Kuhle Family Biomarker Discovery Lab discovers and validates new biomarkers and is developing pinprick “plasma spot” tests from a simple finger-prick blood sample. 

In September, the Arizona Alzheimer’s Disease Research Center received a $22.5 million federal grant from the National Institute on Aging, a five-year renewal to continue its work in the early detection and prevention of the disease.  

Building on success: Efforts by Ashton and others build on decades of statewide research and collaboration, including the work of Dr. Eric Reiman. Reiman and his colleagues founded the Arizona Alzheimer’s Consortium in 1998, Banner Alzheimer’s Institutes in 2006, and Alzheimer’s Prevention Initiative in 2010. He is senior advisor and collaborator at Banner Alzheimer’s Institutes and chair of the Flinn Foundation Board of Directors. 

Takeaway for Arizona: Translational neurosciences is a distinctive area of strength for the Phoenix region, which stands out nationally and globally in biomedical research, clinical expertise, and infrastructure.

Barrow Neurological Institute, TGen including its MindCrowd initiative, Mayo Clinic, and Arizona’s three public universities are also among the leading institutions focused on improving brain health and preventing and treating Alzheimer’s disease. 

We are fortunate to have leading research and clinical trials happening in Arizona cities and towns. Perhaps one day we will be recognized for the breakthrough that ends the disease. 

Portrait of Joshua Lesio

Welcome, Josh Lesio 

We are excited to introduce Josh Lesio as the Flinn Foundation’s new Arizona’s Bioscience Roadmap project manager. 

In this position, Josh will support the Arizona’s Bioscience Roadmap Steering Committee, its members, and workgroups. He also helps monitor the state’s progress in performance metrics and will use data to inform strategic decisions.


Mary O’Reilly, Ph.D.
Vice President, Bioscience Research Programs
Flinn Foundation


FROM THE SOCIALS

LinkedIn post of the month

We’re on LinkedIn, Facebook, Instagram.  #AZBioRoadmap #FlinnFoundation

“It’s obviously a huge honor, and I’m very grateful to have earned the respect of my peers and be elected to this.” – Geoffrey Gurtner, M.D., chair of surgery at the University of Arizona College of Medicine–Tucson, on his election to the National Academy of Medicine.

Share, follow and tag the Flinn Foundation on LinkedIn, Facebook and Instagram. On Bluesky? Look for Arizona’s Bioscience Roadmap. #AZBioRoadmap #FlinnFoundation


COMING SOON

For your calendar

Nov. 16: Behind the Investment: How Xcellerant Ventures Evaluates Opportunities

Nov. 17: Bisnow Phoenix Life Sciences and Biotech Conference

Nov. 19: Arizona Business and Health Summit 2026

Dec. 10: AZBio Trailblazers Luncheon

March 4: Flinn Foundation Bio Capital Conference